Retatrutide has gained significant attention owing to its distinctive way of action. Drugs like semaglutide work through the GLP-1 receptor pathway only. However, retatrutide works on all three metabolic receptors at once – GLP-1, GIP, and glucagon. This gives it a broader pharmacological profile than a GLP-1-only drug. Coskun et al. described LY3437943, the compound […]
Retatrutide is an investigational peptide known as a triple hormone receptor agonist. The term “triple” simply means that retatrutide is designed to activate three different hormone receptors instead of targeting only one. These three receptors are the GLP-1 receptor (GLP-1R), GIP receptor (GIPR), and glucagon receptor (GCGR). Each receptor is involved in metabolic processes such […]
Retatrutide (LY3437943), developed by Eli Lilly and Company, is an investigational peptide currently not approved for human consumption and is under investigation. It works by targeting three hormone receptors: This unique triple-action mechanism makes it different from the rest of the peptides that have been developed for the treatment of various metabolic disorders. There have […]
